Biased allosteric modulators of metabotropic glutamate receptors: novel therapeutic targets for CNS disorders

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1084775

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Metabotropic glutamate receptor 5 (mGlu5) is a major therapeutic target for depression and schizophrenia. The proposed studies will improve our understanding of how drug-like chemicals interact with mGlu5 and therefore change the activity of these receptors and in turn the activity of brain cells leading to therapeutic effectiveness. The research undertaken in this program will allow us to be smarter in developing new mGlu5 drugs that are both effective and have minimal side effects.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $611,534.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Basic Pharmacology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

depression | glutamate receptors | schizophrenia | signalling pathways | structure-function

Related Links